request appointment / exam
To make an appointment or book an examination, complete the form below with your personal details. We will subsequently send you an e-mail with confirmation/instructions.
Please note that information conserving Insurance agreements is merely informative. Therefore, please confirm that your particular Insurance Policy is contracted with us by completing the section “Observations” with your Insurance details.
Alternatively contact us on tel: 282 42 04 00 ( Portugal mainland) 291 00 33 00 (Madeira Island) or by email: email@example.com ( Portugal mainland) firstname.lastname@example.org (Madeira Island) .
All information can also be obtained at the Reception counter of any one of our Hospitals or Clinics.
Your request has been sent to the HPA Group successfully.
We will send send the availability of your appointment as soon as possible.
THE HPA HEALTH GROUP INFORMS ITS PATIENTS THAT IT WILL CONTINUE WITH ALL ITS REGULAR SERVICES WHILE AT THE SAME TIME MAINTAINING ALL THE NECESSARY PROTECTION AND SAFETY MEASURES IN FORCE.
NON-COVID morbidity and mortality has increased significantly,
do not miss appointments, exams and scheduled surgeries.
Mobility restrictions imposed by the state of emergency
do not apply to health services.
You can therefore make your way to our units with confidence.
Learn more on the protection and safety measures currently in force at the HPA HPA Health Group.
An innovative oncology conquest
HPA Magazine 10
This new indication, approved by the FDA in December 2017, is a great advance in the treatment of this aggressive pathology, which has a high probability rate of recurrence following surgery.
Until now, in Europe, there has not been a standard adjuvant therapy recommended after melanoma surgery, because the treatment approved in the USA in 2015 - Ipilimumab (Yervoy®) – caused significant adverse effects in high-risk patients. The CheckMate-238 study compared Nivolumab vs. Ipilimumab and showed quite a significant reduction in recurrence of the disease and risk of death in stage 3 operations (melanoma with node involvement).
After this approval, additional evidence recently came from the KEYNOTE-054 study, which showed a benefit similar to Pembrolizumab (Keytruda®), another immunotherapy drug, in patients with similar characteristics. Therefore, we are witnessing an evolution that exceeds the indications and approvals for immunotherapy in advanced cancer (metastatic/stage 4) – melanoma, lung cancer, kidney cancer, Hodgkin’s lymphoma, cancer of the head and neck – for other pathologies and for earlier stages, which means that we can reduce the risk of this lethal disease recurring after curative surgery, without significant toxicity.
This fact can be explained by the mechanism of action of these drugs. Rather than having a direct cytotoxic effect on the cancerous cells (and also on the healthy cells) as happens with chemotherapy, immunotherapy (also an endovenous drug) acts by unblocking the inhibition of our immune system caused by the cancer and stimulates its cytotoxic action. Thus, in administering a 1-hour simple endovenous treatment, it can be given with a very manageable toxicity profile. At the moment, there are hundreds of clinical trials being carried out to explore the potential of this treatment in earlier stages in the most varied pathologies, isolated or in combination with standard treatments, with extremely promising results.
The HPA is proud to have its Oncology Unit involved in this process, especially the possibility to offer our patients the most advanced oncology treatments available.